Evidence map›Paper›PMID 32294137›Full record

ArticlePLoS pathogens2020

Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.

Leo Yi Yang Lee, Jie Zhou, Rebecca Frise, Daniel H Goldhill, Paulina Koszalka, Edin J Mifsud, Kaoru Baba, Takahiro Noda, Yoshinori Ando, Kenji Sato and 10 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 4 countries.

Leo Yi Yang LeeWHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0001-6704-1235
Jie ZhouDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Rebecca FriseDepartment of Infectious Disease, Imperial College London, London, United Kingdom.ORCID 0000-0002-5522-623X
Daniel H GoldhillDepartment of Infectious Disease, Imperial College London, London, United Kingdom.ORCID 0000-0003-4597-5963
Paulina KoszalkaWHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0002-8346-1624
Edin J MifsudWHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Kaoru BabaShionogi TechnoAdvance Research, Co., Ltd., Osaka, Japan.
Takahiro NodaShionogi TechnoAdvance Research, Co., Ltd., Osaka, Japan.
Yoshinori AndoShionogi & Co., Ltd, Osaka, Japan.
Kenji SatoShionogi & Co., Ltd, Osaka, Japan.
Aoe-Ishikawa YukiShionogi TechnoAdvance Research, Co., Ltd., Osaka, Japan.
Takao ShishidoShionogi & Co., Ltd, Osaka, Japan.
Takeki UeharaShionogi & Co., Ltd, Osaka, Japan.
Steffen WildumF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0001-9779-5740
Elke ZwanzigerF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Neil CollinsonRoche Products Ltd, Welwyn, United Kingdom.
Klaus KuhlbuschF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Barry ClinchRoche Products Ltd, Welwyn, United Kingdom.
Aeron C HurtWHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Wendy S BarclayDepartment of Infectious Disease, Imperial College London, London, United Kingdom.ORCID 0000-0002-3948-0895
Shionogi (Japan) · JPImperial College London · GBRoche (Switzerland) · CHRoche (United Kingdom) · GBAustralian Regenerative Medicine Institute · AUPeter Doherty Institute · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza viruses cause seasonal outbreaks and pose a continuous pandemic threat. Although vaccines are available for influenza control, their efficacy varies each season and a vaccine for a novel pandemic virus manufactured using current technology will not be available fast enough to mitigate the effect of the first pandemic wave. Antivirals can be effective against many different influenza viruses but have not thus far been used extensively for outbreak control. Baloxavir, a recently licensed antiviral drug that targets the influenza virus endonuclease, has been shown to reduce virus shedding more effectively than oseltamivir, a widely used neuraminidase inhibitor drug. Thus it is possible that treatment with baloxavir might also interrupt onward virus transmission. To test this, we utilized the ferret model, which is the most commonly used animal model to study influenza virus transmission. We established a subcutaneous baloxavir administration method in ferrets which achieved similar pharmacokinetics to the approved human oral dose. Transmission studies were then conducted in two different locations with different experimental setups to compare the onward transmission of A(H1N1)pdm09 virus from infected ferrets treated with baloxavir, oseltamivir or placebo to naïve sentinel ferrets exposed either indirectly in adjacent cages or directly by co-housing. We found that baloxavir treatment reduced infectious viral shedding in the upper respiratory tract of ferrets compared to placebo, and reduced the frequency of transmission amongst sentinels in both experimental setups, even when treatment was delayed until 2 days post-infection. In contrast, oseltamivir treatment did not substantially affect viral shedding or transmission compared to placebo. We did not detect the emergence of baloxavir-resistant variants in treated animals or in untreated sentinels. Our results support the concept that antivirals which decrease viral shedding could also reduce influenza transmission in the community.

Indexed as

AnimalsAntiviral AgentsDibenzothiepinsFemaleFerretsInfluenza A Virus, H1N1 SubtypeMorpholinesNeuraminidaseOrthomyxoviridae InfectionsOxazinesPyridinesPyridonesThiepinsTriazinesVirus ReplicationVirus SheddingAntiviral AgentsbaloxavirDibenzothiepinsMorpholinesNeuraminidaseOxazinesPyridinesPyridonesThiepinsTriazines

Identifiers

PMID32294137
PMCPMC7159184
OpenAlexW3015800349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.